Stephens Inc’s Intellia Therapeutics NTLA Stock Holding History

Stephens Inc’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,286	Closed	-$208K	–	1384
2021 Q2	$208K	Buy	+1,286	New	+$100K	﹤0.01%	1190

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Stephens Inc's NTLA Position: Q3 2021 in Review

Stephens Inc sold out of Intellia Therapeutics (NTLA) in Q3 2021, closing a stake of 1,286 shares — an estimated $208K sold.

Stephens Inc first reported a position in NTLA in Q2 2021 and held it in 1 quarter. The position peaked at $208K in Q2 2021. 364 funds tracked by Wall St. Rank hold NTLA as of Q3 2021.

Stephens Inc reported no remaining Intellia Therapeutics position as of Q3 2021 after selling out during the quarter.
Stephens Inc sold 1,286 Intellia Therapeutics shares in Q3 2021, an estimated $208K.
Stephens Inc first reported a position in Intellia Therapeutics in Q2 2021 and held it in 1 quarter.
Stephens Inc's Intellia Therapeutics position peaked at $208K in Q2 2021.
364 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2021.

Based on Stephens Inc's 13F filing for Q3 2021, filed 27 Oct 2021.